Dusa pharmaceuticals inc (DUSA)
CashFlow / Quarterly
Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Net income

-1,421

2,184

-337

3,307

3,506

1,110

-604

Less: income from discontinued operations

-

-

0

-1,151

1,305

-714

33

Net income from continuing operations

-2,274

2,184

-337

10,180

-3,212

396

-570

Accretion of premiums and discounts on marketable securities

0

0

-0

-0

3

4

4

Share-based compensation

670

732

450

322

312

374

196

Depreciation and amortization

140

140

162

112

114

111

106

Loss on change in fair value of warrants

-1,702

1,317

-1,923

-517

2,569

-875

-2,188

Deferred revenues recognized

-0

3

3

7

1,515

85

119

Accounts receivable

135

-716

-376

1,538

85

-532

-587

Inventory

376

180

399

-131

16

497

393

Prepaid and other assets

-135

-204

-132

622

-371

-68

-155

Accounts payable, accrued compensation and other accrued expenses

286

210

-582

-

92

205

-669

Other liabilities

-6

-6

-6

-4

-4

-4

-10

NET CASH PROVIDED BY OPERATING ACTIVITIES FROM CONTINUING OPERATIONS

994

2,680

1,716

3,931

257

1,973

1,467

NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES FROM DISCONTINUED OPERATIONS

-86

-70

-493

66

111

119

112

NET CASH PROVIDED BY OPERATING ACTIVITIES

908

2,609

1,222

3,998

369

2,092

1,579

Purchases of marketable securities

-

-

-

2,998

0

0

1,499

Proceeds from maturities and sales of marketable securities

-

-

-

315

2,250

5,215

3,650

Restricted cash

0

0

0

0

0

0

0

Purchases of property, plant and equipment

10

302

182

192

60

134

75

NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES

1,188

-1,301

-182

-2,876

2,188

5,830

2,074

Stock option exercises

78

61

236

0

0

389

126

Settlements of restricted stock for tax withholding obligations

0

45

463

0

0

42

191

NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES

78

16

-227

0

0

346

-64

NET INCREASE IN CASH AND CASH EQUIVALENTS

2,175

1,323

812

1,122

2,558

8,268

3,589

Decrease (increase) in cash and cash equivalents from discontinued operations

86

70

493

-

-111

-869

-112

Increase in cash and cash equivalents from continuing operations

2,262

1,394

1,306

1,055

2,446

7,399

3,477

Accrued capital expenditures

-

-

215

-

-

-

-